How should hospital pharmacies approach procurement in the Intravenous Immunoglobulin (IVIg) Market?

Pharmacies increasingly qualify two or more brands under multi-source contracts to hedge against allocation during shortages. Brands differ in sugar stabilizers, sodium and IgA content, so formularies should map products to patient risks such as renal impairment or IgA deficiency [20]. Read More

Are IVIg brands clinically interchangeable?

Not automatically. Brands in the Intravenous Immunoglobulin (IVIg) Market are licensed for different indications and vary in osmolality, pH and stabilizer chemistry. Switching should follow clinical review, because product changes have been linked to higher adverse-event rates in sensitive patients [20]. Read More

What makes new entry into the Intravenous Immunoglobulin (IVIg) Market difficult?

Entry requires a secured plasma supply, a licensed fractionation plant and years of regulatory work before first revenue. A greenfield facility typically takes five to seven years to build and validate, so most entrants license technology or partner with established fractionators [8]. Read More

How does subcutaneous immunoglobulin compare with IVIg for patients?

Subcutaneous products deliver steadier IgG trough levels and allow weekly self-infusion at home. IVIg remains preferred for high-dose immunomodulation, where volumes are too large for subcutaneous delivery [20]. Read More

What happens to supply during an IVIg shortage?

Manufacturers move to allocation, distributing product by historical purchase volumes rather than new orders. Health systems respond with demand-management protocols that prioritize primary immunodeficiency, a model Australia formalized through national eligibility criteria [25]. Read More

What should investors watch when evaluating the Intravenous Immunoglobulin (IVIg) Market?

Cost per litre of plasma and grams recovered per litre drive margins more than list price. Investors should also track albumin and alpha-1 demand, since those co-products absorb the rest of each litre [7]. Read More

Do biosimilar or recombinant alternatives threaten IVIg?

No biosimilar IVIg exists because the product is a polyclonal pool from thousands of donors. Recombinant polyclonal antibodies remain in early development, so plasma-based supply should dominate the Intravenous Immunoglobulin (IVIg) Market through 2035 [20]. Read More

Intravenous Immunoglobulin Market (2026 - 2035)

ID: MRFR/HC/2259-HCR 200 Pages Satyendra Maurya Last Updated: October 07, 2026

Intravenous Immunoglobulin (IVIG) Market Research Report By Application (Immunodeficiency Disorders, Neurological Disorders, Autoimmune Disorders, Infectious Diseases), By End Use (Hospitals, Clinics, Homecare, Pharmaceutical Companies), By Product Type (Intravenous Immunoglobulin, Subcutaneous Immunoglobulin, Combination Therapies), By Source (Human Plasma, Recombinant Techniques) and By Region (North America, Europe, South America, Asia Pacific, Middle East and Africa) -Forecast to 2035

Intravenous Immunoglobulin Market

Market Size

Forecast Period2026-2035

CAGR (2026-2035)6.85%

2025 Market SizeUSD 17.67 Billion

2035 Market SizeUSD 34.33 Billion

Key Players

CSL Behring

Grifols

Takeda

Octapharma

Kedrion Biopharma

Shanghai RAAS

Trends

Rising Diagnosis of Primary Immunodeficiency
Label Expansion in Neurology
Plasma Collection Capacity Expansion

Opportunities

Emerging-Market Fractionation and Contract Manufacturing
Home Infusion Services and Outcomes-Based Contracting
High-Concentration and Faster-Infusion Formats

Summary Table of Contents Segmentation Download PDF

1 Market Summary | |
2 Key Report Takeaways | |
1. 2.1 By Immunoglobulin Class | |
2. 2.2 By Application | |
3. 2.3 By End User | |
4. 2.4 By Region | |
3 Market Size and Forecast (2021–2035) | |
4 Driver Impact Analysis | |
1. 4.1 Rising Diagnosis of Primary Immunodeficiency | |
2. 4.2 Label Expansion in Neurology | |
3. 4.3 Plasma Collection Capacity Expansion | |
4. 4.4 Secondary Immunodeficiency in Hematologic Cancer | |
5. 4.5 Plasma Self-Sufficiency Programs in Emerging Economies | |
6. 4.6 Home-Infusion Reimbursement Expansion | |
5 Restraints Impact Analysis | |
1. 5.1 Plasma Supply Constraints and Rising Collection Cost | |
2. 5.2 Competition from FcRn Inhibitors and Targeted Biologics | |
3. 5.3 High Therapy Cost and Payer Utilization Controls | |
4. 5.4 Donor Compensation Limits and Import Dependence in Europe | |
5. 5.5 Thromboembolic and Renal Safety Risks | |
6 Opportunities | |
1. 6.1 Emerging-Market Fractionation and Contract Manufacturing | |
2. 6.2 Home Infusion Services and Outcomes-Based Contracting | |
3. 6.3 High-Concentration and Faster-Infusion Formats | |
4. 6.4 New Immunomodulatory Indications | |
5. 6.5 Gulf and North African Capacity Partnerships | |
7 Regional Market Share and Country-Level Analysis | |
1. 7.1 North America | | |
  1. 7.1.1 US | | |
  2. 7.1.2 Canada | | |
  3. 7.1.3 Mexico | |
2. 7.2 Europe | | |
  1. 7.2.1 Germany | | |
  2. 7.2.2 UK | | |
  3. 7.2.3 France | | |
  4. 7.2.4 Italy | | |
  5. 7.2.5 Spain | | |
  6. 7.2.6 Nordic Countries | | |
  7. 7.2.7 Russia | | |
  8. 7.2.8 Rest of Europe | |
3. 7.3 Asia-Pacific | | |
  1. 7.3.1 China | | |
  2. 7.3.2 India | | |
  3. 7.3.3 Japan | | |
  4. 7.3.4 South Korea | | |
  5. 7.3.5 ASEAN | | |
  6. 7.3.6 Rest of Asia-Pacific | |
4. 7.4 South America | | |
  1. 7.4.1 Brazil | | |
  2. 7.4.2 Argentina | | |
  3. 7.4.3 Rest of South America | |
5. 7.5 Middle East & Africa | | |
  1. 7.5.1 Saudi Arabia | | |
  2. 7.5.2 UAE | | |
  3. 7.5.3 South Africa | | |
  4. 7.5.4 Egypt | | |
  5. 7.5.5 Rest of MEA | |
8 Future Outlook (2026–2035) | |
1. 8.1 Industrialized Plasma Collection and Donor Analytics | |
2. 8.2 Competitive Reset from Targeted Immunology | |
3. 8.3 Decentralized Care and Subcutaneous Crossover | |
4. 8.4 Supply Security as Health Policy | |
9 Segmentation Analysis | |
1. 9.1 By Immunoglobulin Class | | |
  1. 9.1.1 IgG | | |
  2. 9.1.2 IgA | | |
  3. 9.1.3 IgM | | |
  4. 9.1.4 Others | |
2. 9.2 By Application | | |
  1. 9.2.1 Hypogammaglobulinemia | | |
  2. 9.2.2 Chronic Inflammatory Demyelinating Polyneuropathy | | |
  3. 9.2.3 Primary Immunodeficiency | | |
  4. 9.2.4 Myasthenia Gravis | | |
  5. 9.2.5 Multifocal Motor Neuropathy | | |
  6. 9.2.6 Others | |
3. 9.3 By End User | | |
  1. 9.3.1 Hospitals | | |
  2. 9.3.2 Specialty Clinics & Neurology Centers | | |
  3. 9.3.3 Home Care Settings | | |
  4. 9.3.4 Others | |
10 Competitive Landscape | |
1. 10.1 Market Concentration Analysis | |
2. 10.2 Competitive Benchmarking Matrix | |
3. 10.3 Company Profiles | | |
  1. 10.3.1 CSL Behring | | |
  2. 10.3.2 Grifols | | |
  3. 10.3.3 Takeda | | |
  4. 10.3.4 Octapharma | | |
  5. 10.3.5 Kedrion Biopharma | | |
  6. 10.3.6 Shanghai RAAS | | |
  7. 10.3.7 Biotest AG | | |
  8. 10.3.8 LFB | | |
  9. 10.3.9 GC Biopharma | | |
  10. 10.3.10 ADMA Biologics | |
11 Recent News & Developments | |
12 Report Scope and Methodology | |
13 Detailed Sources and Citations | |
14 Frequently Asked Questions (FAQs) | | LIST OF TABLES | |
TABLE 1 Global IVIg Market Summary Snapshot, 2025–2035 | |
TABLE 2 Global IVIg Market Size & Forecast, by Revenue (USD Billion), 2021–2035 | |
TABLE 3 Driver Impact Analysis, 2026–2035 | |
TABLE 4 Restraints Impact Analysis, 2026–2035 | |
TABLE 5 Global IVIg Market, Regional Summary, 2025 | |
TABLE 6 North America IVIg Market, by Country, 2025–2035 | |
TABLE 7 Europe IVIg Market, by Country, 2025–2035 | |
TABLE 8 Asia-Pacific IVIg Market, by Country, 2025–2035 | |
TABLE 9 South America IVIg Market, by Country, 2025–2035 | |
TABLE 10 Middle East & Africa IVIg Market, by Country, 2025–2035 | |
TABLE 11 Global IVIg Market, by Immunoglobulin Class, 2021–2035 (USD Billion) | |
TABLE 12 Global IVIg Market, by Application, 2021–2035 (USD Billion) | |
TABLE 13 Global IVIg Market, by End User, 2021–2035 (USD Billion) | |
TABLE 14 Competitive Benchmarking Matrix, 2025 | |
TABLE 15 Report Scope and Methodology | |
TABLE 16 Detailed Sources and Citations | | LIST OF FIGURES | |
FIGURE 1 Global IVIg Market Dynamics Overview | |
FIGURE 2 IVIg Industry Value Chain Analysis | |
FIGURE 3 Porter's Five Forces Analysis | |
FIGURE 4 Global IVIg Market Size Trend, 2021–2035 (USD Billion) | |
FIGURE 5 Market Share by Immunoglobulin Class, 2025 | |
FIGURE 6 Market Share by Application, 2025 | |
FIGURE 7 Market Share by End User, 2025 | |
FIGURE 8 Regional Market Share, 2025 | |
FIGURE 9 Regional Growth Comparison, 2026–2035 | |
FIGURE 10 Competitive Landscape Share Analysis, 2025

Certified Researchers

Enquiry

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Immunoglobulin Class	IgG, IgA, IgM, Others	IgG (79.2% share)	IgG (fastest-growing class)
By Application	Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Primary Immunodeficiency, Myasthenia Gravis, Multifocal Motor Neuropathy, Others	Hypogammaglobulinemia (34.4% share)	Myasthenia Gravis (8.45% CAGR)
By End User	Hospitals, Specialty Clinics & Neurology Centers, Home Care Settings, Others	Hospitals (47.2% share)	Specialty Clinics & Neurology Centers (8.70% CAGR)
By Region	North America, Europe, Asia-Pacific, South America, Middle East & Africa	North America (44.6% share)	Asia-Pacific (8.9% CAGR)

Market Segmentation Overview

By Immunoglobulin Class

Sub-Segment	Key Trend
IgG	High-strength 10% and 20% formulations shorten infusion time
IgA	Limited to research and specialty preparations
IgM	IgM-enriched products used in severe infection protocols
Others	Hyperimmune and specialty globulins

IgG leads and grows fastest because every licensed product for immunodeficiency and neurology is an IgG preparation, and new brands compete on purity and infusion speed. IgM keeps a defined niche in IgM-enriched sepsis protocols in parts of Europe. IgA remains marginal, with no major licensed intravenous indication.

By Application

Sub-Segment	Key Trend
Hypogammaglobulinemia	Stable demand from established replacement guidelines
Chronic Inflammatory Demyelinating Polyneuropathy	High-dose maintenance under FcRn competition
Primary Immunodeficiency	Earlier diagnosis via newborn screening
Myasthenia Gravis	Earlier use in exacerbations and crises
Multifocal Motor Neuropathy	First-line labelled therapy with few alternatives
Others	Kawasaki disease, ITP and emerging off-label uses

Hypogammaglobulinemia holds the largest share because replacement dosing is lifelong and guideline-backed. Myasthenia Gravis grows fastest as neurologists use IVIg earlier in crises, though FcRn inhibitors will contest maintenance use. Chronic Inflammatory Demyelinating Polyneuropathy remains the largest gram consumer per patient, which makes it the indication most exposed to targeted-biologic substitution.

By End User

Sub-Segment	Key Trend
Hospitals	First infusions and acute neurology care
Specialty Clinics & Neurology Centers	Payer steering to lower-cost sites
Home Care Settings	Growth under the permanent CMS home benefit
Others	Physician-office and ambulatory infusion

Hospitals lead because first doses and crisis treatment require monitored settings. Specialty Clinics & Neurology Centers grow fastest as payers shift stable maintenance patients away from hospital outpatient rates. Home Care Settings are gaining ground under the CMS benefit, but remain limited to stable patients with good infusion tolerance.

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”